- Home
- SPKL vs ACRV Comparison
SPKL vs ACRV Comparison
Compare SPKL & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPKL
- ACRV
- Stock Information
- Founded
- SPKL 2021
- ACRV 2018
- Country
- SPKL United States
- ACRV United States
- Employees
- SPKL N/A
- ACRV 61
- Industry
- SPKL
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- SPKL
- ACRV Health Care
- Exchange
- SPKL Nasdaq
- ACRV Nasdaq
- Market Cap
- SPKL 176.5M
- ACRV 73.5M
- IPO Year
- SPKL 2023
- ACRV 2022
- Fundamental
- Price
- SPKL $10.76
- ACRV $2.24
- Analyst Decision
- SPKL
- ACRV Strong Buy
- Analyst Count
- SPKL 0
- ACRV 6
- Target Price
- SPKL N/A
- ACRV $21.80
- AVG Volume (30 Days)
- SPKL 3.8K
- ACRV 162.1K
- Earning Date
- SPKL 01-01-0001
- ACRV 05-13-2025
- Dividend Yield
- SPKL N/A
- ACRV N/A
- EPS Growth
- SPKL N/A
- ACRV N/A
- EPS
- SPKL 0.19
- ACRV N/A
- Revenue
- SPKL N/A
- ACRV N/A
- Revenue This Year
- SPKL N/A
- ACRV N/A
- Revenue Next Year
- SPKL N/A
- ACRV N/A
- P/E Ratio
- SPKL $56.04
- ACRV N/A
- Revenue Growth
- SPKL N/A
- ACRV N/A
- 52 Week Low
- SPKL $10.26
- ACRV $2.14
- 52 Week High
- SPKL $11.95
- ACRV $11.90
- Technical
- Relative Strength Index (RSI)
- SPKL 56.91
- ACRV 22.41
- Support Level
- SPKL $10.74
- ACRV $5.00
- Resistance Level
- SPKL $10.77
- ACRV $5.65
- Average True Range (ATR)
- SPKL 0.01
- ACRV 0.44
- MACD
- SPKL -0.00
- ACRV -0.33
- Stochastic Oscillator
- SPKL 50.00
- ACRV 2.85
About SPKL Spark I Acquisition Corp.
Spark I Acquisition Corp is a Blank check company.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.